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 Abstract 
  Background:  Blood-based biomarkers of atherosclerosis have been used to identify patients at 
high risk for developing stroke. We hypothesized that patients with carotid artery disease would 
have a distinctive proteomic signature in blood as compared to a healthy control population 
without carotid artery disease. In order to discover protein biomarkers associated with increased 
atherosclerotic risk, we used two different strategies to identify biomarkers from patients with 
clinically defined atherosclerosis who were undergoing endarterectomy for atherosclerotic ca-
rotid artery disease. These patients were compared with healthy matched controls.   Methods:  
Serum was obtained from patients undergoing endarterectomy (EA; n = 38) and compared to 
a group of age-matched healthy controls (n = 40). Serum was fractionated using anion exchange 
chromatography and three different surface-enhanced laser desorption/ionization (SELDI) chip 
surfaces and then evaluated with mass spectrometry (MS) and two-dimensional difference gel 
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electrophoresis (2D-DIGE).   Results:   A random forest (RF) analysis of the SELDI-MS protein peak 
data distinguished these two groups with 69.2% sensitivity and 73.2% specificity. Four unique 
SELDI peaks (4.2, 4.4, 16.7 and 28 kDa, all p !  0.01) showed the greatest influence in the RF mod-
el. The EA patients with a history of prior clinical atherosclerotic plaque rupture manifested as 
either stroke or transient ischemic attack (symptomatic; n = 16) were compared to patients with 
carotid atherosclerosis but no clinical evidence of plaque rupture (asymptomatic; n = 22). Anal-
ysis of the SELDI spectra did not separate these two patient subgroups. A subgroup analysis 
using 2D-DIGE images obtained from albumin-depleted serum comparing symptomatic (n = 
10) to asymptomatic EA patients (n = 10) found 4 proteins that were differentially expressed 
(p   !   0.01) in the symptomatic patients. These proteins were identified as     1 -antitrypsin,  hapto-
globin and vitamin D binding protein that were downregulated and     2 -glycoprotein  precursor 
that was upregulated in the symptomatic EA group.   Conclusions:   SELDI-MS data analysis of 
fractionated serum suggests that a distinct protein signature exists in patients with carotid ath-
erosclerosis compared to age-matched healthy controls. Identification of 4 proteins in a subset 
of patients with symptomatic and asymptomatic carotid atherosclerosis suggests that these 
and other protein biomarkers may assist in identifying high-risk patients with carotid athero-
sclerosis.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Atherosclerosis is an inflammatory disease that affects medium and large arteries. Im-
mune mechanisms underlie both the formation and activation of atherosclerotic plaques that 
cause ischemia from vessel stenosis or plaque rupture with thrombosis   [1, 2]  . The discovery 
of biomarkers that improve current methods of diagnosis and treatment of cerebral ischemia 
would be a valuable addition to patient care. Several categories of protein biomarkers that 
reflect brain tissue damage, inflammation, vascular injury, hemostasis or neuroendocrine 
responses have helped to delineate mechanisms and potential pathways for new therapies 
  [3–5]  . Similarly, microarray profiles of ribonucleic acid expression in blood can distinguish 
ischemic stroke from controls and other types of brain injury  [6] . Single nucleotide polymor-
phisms of genes that regulate inflammatory pathways have been associated with an increased 
relative risk for ischemic stroke   [7–10]  . However, due to the heterogeneity of causes of isch-
emic stroke and the lack of sufficient sensitivity and specificity, none of these markers are 
currently used routinely to assess risk, and diagnose, treat, or provide prognosis of cerebral 
ischemic events   [3–5, 11]  .
  Some of the biomarkers assessing risk associated with carotid artery disease are similar to 
those associated with cardiovascular risk, such as C-reactive protein or fibrinogen   [12]  . Blood 
levels of cholesterol and associated lipoproteins have a well-known relationship to the risk of 
coronary artery disease, yet this relation is only weakly associated in ischemic stroke suggest-
ing possible differences in mechanisms or susceptibility of the different vascular beds to ath-
erogenesis   [13–15]  . A recent systematic review of biomarkers associated with stroke risk and 
best therapy for carotid artery disease noted the heterogeneity of results from the studies of 
different biomarkers   [12]  . Clarifying the role of inflammatory markers that are predictive of 
carotid artery disease within a background of systemic atherosclerosis remains challenging.
    In order to discover new protein biomarkers associated with increased atherosclerotic 
risk, we conducted a pilot study in patients with and without carotid artery disease. We hy-
pothesized that patients with carotid artery disease would have a distinctive proteomic sig-
nature in blood as compared to a healthy control population. Our goal was to identify sero-
logical markers that would help distinguish patients with and without carotid atherosclero-117
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sis and those who were more likely to become symptomatic. We used two different strategies 
to identify biomarkers from patients with clinically defined atherosclerosis who were under-
going endarterectomy (EA) for carotid artery disease. We characterized the entire proteome 
in these patients by fractionating serum using anion exchange and then fractionating further 
using three different protein chip surfaces for screening with surface-enhanced laser desorp-
tion/ionization (SELDI)-time of flight (TOF) mass spectrometry (MS). A bioinformatic ap-
proach to establish multivariate classification models based on SELDI-MS data was used to 
distinguish the atherosclerosis group from the no atherosclerosis group. Samples from the 
symptomatic and asymptomatic EA group were analyzed using two-dimensional difference 
gel electrophoresis (2D-DIGE), matrix-assisted laser desorption/ionization (MALDI) tan-
dem MS (MS/MS) and liquid chromatography MS/MS. Our results demonstrate both the 
utility and limitations of protein profiling using these approaches.
  Materials  and  Methods 
 Sample  Collection 
 The atherosclerosis group was composed of 38 patients who had blood samples obtained 
prior to EA with carotid plaque removal. The control group consisted of 40 age-matched 
healthy subjects who were enriched for atherosclerotic risk factors but had no clinical evi-
dence of atherosclerosis at the time of sampling. The atherosclerosis group was composed of 
both symptomatic (n = 16) and asymptomatic (n = 22) patients who underwent EA. The 
symptomatic patients underwent EA surgery after a prior stroke or transient ischemic attack 
(TIA) and met the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
criteria for symptomatic atherosclerosis   [16]  . The asymptomatic atherosclerotic patients had 
no prior clinical sequelae from their vascular disease.  Table 1  lists their baseline clinical char-
acteristics. Serum from all patients who consented to participation was collected at the Na-
tional Naval Medical Center under an institutional review board-approved protocol during 
outpatient visits prior to EA or in outpatient visits as appropriate. The serum was stored at 
–80    °    C before use. In symptomatic patients, samples were obtained within 1–4 weeks after 
TIA or stroke. The strokes were mild to moderate in severity.
  Sample  Fractionation 
  Prior to generating protein expression profiles by SELDI analysis, serum samples were 
processed by anion exchange chromatography using a 96-well serum fractionation kit con-
taining anion exchange resin according to the manufacturer’s recommendations (Ciphergen 
Biosystems, Fremont, Calif., USA) and automated for high-throughput liquid handling on a 
Biomek 2000 automated workstation (Beckman Coulter, Fullerton, Calif., USA). Six total 
fractions with buffers of 50 m  M   Tris-HCl, 0.1% N-octyl-   - D  -glucoside (OGP; pH 9; F1); 50 
m  M   HEPES, 0.1% OGP (pH 7; F2); 100 m  M   Na acetate (pH 5; F3); 100 m  M   Na acetate, 0.1% 
OGP (pH 4; F4); 50 m  M   Na citrate, 0.1% OGP (pH 3; F5), and 33.3% isopropanol, 16.7% ace-
tonitrile and 0.1% trifluoroacetic acid (TFA; organic, F6) were collected (  fig. 1  ). Each of the 
six 200-    l fractions was then stored at –80    °    C until application to the ProteinChip arrays.
  SELDI  ProteinChip  Analysis 
  Mass spectra from serum protein expression profiles were obtained using immobilized 
metal affinity capture (IMAC30), strong anion exchange (Q10) and/or weak cation exchange 
(CM10) ProteinChip arrays (Ciphergen Biosystems) and run in duplicate according the man-
ufacturer’s recommended protocols. All sample preparations, including deposition of ma-
trix, were performed on a Biomek 2000 automated work station using two 96-well Bioproces-118
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sors from Ciphergen. For quality control purposes and to measure the chip-to-chip experi-
mental variation, a pooled serum sample was prepared by mixing control and patient samples, 
and applied to 1 spot on each ProteinChip array used. The coefficients of variation (CV) of 
the intensity of each detectable peak were measured and the average variation across the en-
tire range was   !  25%. Spectra from each sample were generated using a high and low laser 
intensity reading in order to optimize the detection of both low and higher molecular weight 
proteins. Prior to all chip reading, the instrument performance was evaluated by measuring 
laser energy output, resolution and sensitivity, and then externally calibrated using standard 
calibrants spanning the user-defined range of the mass/charge ratio.
Table 1. C  linical characteristics of all patients
No clinical 
atherosclerosis
(n = 40)
Atherosclerosis
(n = 38)
p value
Males/females 32/8 31/7 1.0
Age, years 71.288.3 70.089.5 0.59
Smoking
Never
Quit
Active
25
13
2
11
20
7
0.004
0.45
0.08
Hypertension 17 36 <0.001
High cholesterol 12 29 0.003
Diabetes 1 9 0.023
Atrial fibrillation 0 4 0.05
CAD
CABG
0
0
16
8
<0.001
0.002
Angina 0 8 0.01
MI 0 6 0.01
PVD 
Claudication
0
0
15
13
<0.001
<0.001
Prior stroke or TIA 0 16 <0.001
Glucose, mg/dl 92815 110847 0.03
Triglycerides, mg/dl 132858 151893 0.30
Cholesterol, mg/dl 203830 177834 <0.001
HDL, mg/dl 58813 45811 <0.001
LDL, mg/dl 123830 103826 0.003
VLDL, mg/dl 26811 28811 0.46
WBC, 109/l 5.9280.79 7.3282.19 <0.001
Platelets, 109/l 239864 230857 0.5
Fibrinogen, mg/dl 358851 382898 0.19
ESR, mm/h 11881 8 816 0.01
C-reactive protein 
<1 mg/l
1–3 mg/l
>3 mg/l
Not done
36
1
0
3
32
5
1
0
0.51
0.10
0.48
C AD = Coronary artery disease; CABG = coronary artery bypass graft; ESR = erythrocyte sedimenta-
tion rate; MI = myocardial infarction; PVD = peripheral vascular disease. Data are means 8 SD. Com-
parisons of the groups (no clinical atherosclerosis vs. atherosclerosis) were done using either an unpaired 
t test or Fisher’s exact test (InStat 3, version 3.0b, GraphPad Software) with nominal p values reported.119
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  SELDI-MS  Bioinformatic  Analysis 
  All SELDI-MS spectra were processed similarly using CiphergenExpress 2.1 data man-
agement software (Ciphergen Biosystems). Initially, both raw and processed data were ana-
lyzed. For spectrum-processing parameters, the general approach was the determination of 
the optimal baseline subtraction and smoothing algorithms, a total ion current normaliza-
tion across all spectra, followed by a recalibration using peak alignment. A peak detection 
algorithm, using modifiable values for signal to noise and peak valley depth, was then em-
ployed to select peaks from a set of spectra from the same fraction and chip type. A Mann-
Whitney U test was used to compare the mean intensity value of each recognized peak be-
tween two different clinical groups. The random forest (RF) program, which is a machine-
learning classifier algorithm that makes group predictions based on many potentially 
correlated variables, was used to develop the multivariate classification models   [17]  .
    Albumin Depletion from Serum 
  Samples to be analyzed by 2D gels were albumin depleted using four Seppro Human 
Albumin IgY bead columns (Genway Biotech, San Diego, Calif., USA). Each serum sample 
was run through a column two times to obtain sufficient concentration of albumin-deplet-
ed serum proteins. Albumin-depleted and albumin-bound fractions were both recovered 
from the column and stored at –80    °    C. Symptomatic and asymptomatic samples were ran-
domized with respect to columns. After all depletions, samples were thawed and a bicin-
choninic acid assay (Pierce Biotechnology, Rockford, Ill., USA) was run to determine the 
protein concentration of the depleted and bound fractions for each sample. Samples were 
then stored at 4    °   C.
  Fig. 1.   Four unique SELDI-MS peaks that showed the greatest influence in distinguishing atherosclerosis 
samples from patient samples with no evidence of atherosclerosis. 120
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    2D-DIGE and Image Analysis 
  Detailed protocols for sample preparation, fluorescent labeling, 2D-PAGE and image 
acquisition are presented in the online supplementary experimental protocol (for all online 
suppl. material, see www.karger.com/doi/10.1159/000334477). Briefly, after sample cleaning 
and denaturing, 25     g of protein were used for the Cy2 standard pool. Albumin-depleted 
serum samples from symptomatic and asymptomatic EA patients were labeled using either 
Cy3 or Cy5 dye. The remaining non-labeled samples were pooled to create a physical average 
for a Coomassie-stained spot picking gel. Minimal labeling uses 50     g of protein with 1    l 
of 400 pmol DIGE dye. Amersham IPG Immobiline Drystrips (pH 3–10 NL, 24 cm) and 18 
cm 4–12% gradient Precast gels (Jule, Milford, Conn., USA) were used for the 1st and 2nd 
dimensions. These gels were run using the Ettan DALT 12 system (Amersham Biosciences, 
Piscataway, N.J., USA). All gels were imaged using a Fuji Film FLA-5000 scanner and Image-
View software. The picking gel was scanned using a laser wavelength at 473 nm with a long-
pass blue filter. The image was saved as a 16-bit image with a resolution of 10     m. DIGE gels 
were scanned twice using appropriate laser and filter settings for Cy3 and Cy5. The 2D-DIGE 
images were uploaded to www.ludesi.com and analyzed for spot detection, segmentation and 
matching using the image analysis software, Ludesi 2D Interpreter.
  Protein  Identification 
  Tryptic in-Gel Digestion.   For 2D-DIGE experiments a picking gel for protein identifica-
tion, was run simultaneously and stained with Coomassie blue. Protein spots of interest were 
excised from the gel and the gel plugs were digested with the trypsin profile IGD kit (Sigma, 
St. Louis, Mo., USA) or modified trypsin (Promega, Madison, Wisc., USA) according to the 
manufacturers’ protocols. For protein identification using high-resolution MALDI-MS/MS, 
the digested sample was desalted with Vivapure C18 micro spin column or C18 ZipTip (Wa-
ters, Milford, Mass., USA) and eluted with 3     l 60% ACN with 0.1% TFA.
    High-resolution MALDI-TOF-TOF was acquired using an ABI 4700 proteomics ana-
lyzer (Applied Biosystems, Foster City, Calif., USA) operating in positive ion reflectron mode 
at 20 kV. The sample (0.5   l) was mixed with 0.5   l of the MALDI matrix (5 mg/ml of CHCA 
in 50% ACN and 0.1% TFA) and spotted onto the plate. The instrument was calibrated prior 
to analysis. The acquired spectra were submitted to MASCOT to search for matched proteins 
with human SPROT protein database.
    Detailed experimental protocols are described in the online supplementary experimen-
tal protocols.
  Results   
 Patient  Characteristics 
  Demographics and clinical characteristics of the patients with and without atheroscle-
rosis are summarized in   table 1  . Fifteen of 20 clinical variables were statistically different in 
the patients with atherosclerosis (e.g. coronary artery disease, peripheral vascular disease, 
angina, diabetes, hypertension and hypercholesterolemia). In contrast, comparisons of these 
clinical variables in patients with atherosclerosis who were symptomatic versus those who 
were asymptomatic prior to EA (  table 2  ) showed that other than the history of a previous 
ischemic event, none of the clinical variables were different between these two groups.
  SELDI-MS  Profiling 
  Univariate analysis of the SELDI data comparing the atherosclerosis patient group (n = 
38) to non-atherosclerotic controls identified 42 peaks with p  !  0.01 by Mann-Whitney t tests 121
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of mean peak intensity (listed in online suppl. table 1). We utilized 3 different ProteinChip 
surfaces with different binding properties. The number of unique peaks will therefore be less 
as some of the proteins will bind to more than one SELDI surface resulting in an overlap of 
the peaks between chips. 
  In order to better classify the groups based on SELDI protein peak data, RF analysis was 
applied to the data set for an unbiased estimate of correct prediction rates  [18] . The RF mod-
el demonstrated 69.2% sensitivity and 73.2% specificity in atherosclerosis prediction. The 
metric multidimensional scaling representation of the proximity matrix is shown in   figure 
2  . Dimension (Dim) 1 and Dim 2 are approximations to the first two principal components 
Table 2. C  linical characteristics of the patients with atherosclerosis
A therosclerosis p  value
sy mptomatic
(n = 16)
asymptomatic
(n = 22)
Males/females 14/2 17/5 0.67
Age, years 70.1812.3 70.087.4 0.96
Smoking
Never
Quit
Active
5
9
2
6
11
5
0.49
1.0
0.67
Hypertension 14 22 0.17
High cholesterol 10 19 0.12
Diabetes 5 4 0.44
Atrial fibrillation 1 3 0.62
CAD
CABG
6
2
10
8
0.74
0.14
Angina 2 6 0.42
MI 2 4 1.0
PVD
Claudication
5
4
10
9
0.50
0.48
Prior stroke or TIA 16 0 <0.001
Glucose, mg/dl 101816 115860 0.37
Triglycerides, mg/dl 132854 1648115 0.31
Cholesterol, mg/dl 171835 181833 0.36
HDL, mg/dl 42810 46812 0.20
LDL, mg/dl 103832 103820 0.93
VLDL, mg/dl 27811 29812 0.66
WBC, 109/l 6.9681.77 7.5882.51 0.40
Platelets, 109/l 220867 237848 0.36
Fibrinogen, mg/dl 382889 3818108 0.99
ESR, mm/h 16813 20818 0.47
C-reactive protein
<1 mg/l
1–3 mg/l
>3 mg/l
Not done
14
2
0
0
18
3
1
0
1.0
1.0
1.0 
CAD  = Coronary artery disease; CABG = coronary artery bypass graft; ESR = erythrocyte sedimenta-
tion rate; MI = myocardial infarction; PVD = peripheral vascular disease. Data are means 8 SD. Com-
parisons of the two groups (symptomatic vs. asymptomatic atherosclerosis) were done using either an 
unpaired t test or Fisher’s exact test (InStat 3, version 3.0b, GraphPad Software) with nominal p values 
reported.122
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of the similarity space defined by the model. Based on significance weighting of specific 
peaks in the RF models, the signal intensity of 4 unique SELDI peaks showed the greatest 
influence in distinguishing atherosclerosis samples from control patient samples (online 
suppl. fig. 2). SELDI-derived peaks had p   !   0.01 by univariate analysis. The 4 unique SELDI 
peaks were: 4.2 kDa (Q10, F6), 16.7 kDa (IMAC, F1), 4.4 kDa (CM10, F1) and 28 kDa (Q10, 
F5), with the chip type and anion-exchange fraction listed following the molecular mass of 
the peak. Based on our previous publication   [19]  , the 28.1-kDa peak is apolipoprotein A  1  
(ApoA  1  ). We did not attempt to further identify the 4.2-, 4.4- and 16.7-kDa peaks.
    SELDI-MS Profiling of Symptomatic versus Asymptomatic EA Groups               
  We analyzed SELDI peak data to compare asymptomatic EA patients to symptomatic 
EA patients. RF analysis failed to develop models with high sensitivity and specificity. The 
balanced RF (average over 10 RF runs) yielded a sensitivity of 28.8% and a specificity of 
52.7%.
    2D-DIGE with Protein Identification of Differentially Expressed Proteins in the 
Symptomatic and Asymptomatic EA Groups 
  2D-DIGE analysis of albumin-depleted serum on the 20 randomly selected samples re-
vealed 11 spots with p   !   0.01 (  fig. 3  ). Absolute spot intensity and volumes, p values and pro-
tein identification of these differentially expressed spots are shown in  table 3 . Using MALDI-
MS/MS and liquid chromatography MS/MS, 8 of the 11 proteins that were differentially ex-
pressed were identified ( table 3 ). Four of these spots were identified as belonging to the same 
parental protein molecule haptoglobin (HPT) and 2 were related to     1 -antitrypsin  (A 1 AT), 
both of which were downregulated in patients in the symptomatic EA group. It is likely that 
these spots represent proteins that are alternative splice variants or posttranslationally mod-
ified versions of the parental protein. Vitamin D binding protein (VTDB) was downregu-
lated in the symptomatic EA, and leucine-rich    2 -glycoprotein precursor (LRG) was upregu-
lated in the symptomatic EA group (  fig. 4  ). 
  Discussion 
  Carotid atherosclerosis is one of the primary causes of ischemic stroke   [20]  . Endothelial 
activation due to inflammation at the site of the carotid plaque as well as systemic inflam-
mation may contribute to thrombus formation   [20–22]  . Examination of carotid plaques re-
  Fig. 2.   Multidimensional scaling representation of 
the proximity matrix for the RF analysis of athero-
sclerosis versus no atherosclerosis. Atherosclerosis 
samples are distinguished from no-atherosclerosis 
samples. Dim 1 and Dim 2 are approximations to 
the first two principal components of the similarity 
space defined by the model. 123
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  Fig. 3.  A representative 2D-DIGE 
image consisting of a single Cy5-
labeled symptomatic EA patient 
serum, a Cy3-labeled asymp-
tomatic EA patient serum and a 
Cy2-labeled internal standard 
control sample. The spots indi-
cated with circles locate the posi-
tion of the 11 differentially ex-
pressed spots with p   !   0.01. 
Table 3. P  rotein identification by MALDI-MS/MS and liquid chromatography-MS/MS for spots differentially expressed 
between symptomatic and asymptomatic EA patients using 2D-DIGE
S pot  No. 
(identifier)
Mean av  erage spot volume8SD p value Protein 
ID
MASCOT 
score
Peptides
asymptomati c symptomatic
1 1,0928313 7678165 0.0039 HPT 141 GSFPWQAR
(16,674) VGYVSGWGR
VTSIQDWVQK
DIAPTLTLYVGK
SCAVAEYGVYVK (C)
YVMLPVADQDQCIR (C)
YVMLPVADQDQCIR (C) (M)
SPVGVQPILNEHTFCAG (C) (M)
2 7808219 5358121 0.0029 HPT 82 YEELQITITAGR
(16,681) LALDLEIATYR
WELLQQVDTSTR
THNLEPYFESFINNLR
HPT 45 VGYVSGWGR
YVMLPVADQDQCIR (C) (M)
3 563868 426882 0.0007 VTDB 84 YTFELSR
(16,682) THLPEVFLSK
HLSLLTTLSNR
EDFTSLSVLYSR
4 535887 375866 0.0001 KAC 58 SGTASVVCLLNNFYPR (C)
(16,723) TVAAPSVFIFPPSDEQLK
ADPGK 22 LAAAWDALIVRPVRR
PF21B 21 LASNYLNNPLFLTAR
GSELQNEHQQLEEERDR
5 169858 3178106 0.0005 HPT 66 VGYVSGWGR
(16,770) VTSIQDWVQK
YVMLPVADQDQCIR (C)
YVMLPVADQDQCIR (C) (M)124
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moved from patients with ischemic strokes found that ulceration and thrombosis are more 
common in symptomatic patients   [21]  . Identifying proteins from the blood proteome that 
influence inflammation in patients with carotid atherosclerosis may provide some insight 
into the cause of thrombus formation and serve as potential biomarkers to identify patients 
at risk for developing symptomatic carotid atherosclerosis.
    We hypothesized that differences in serum proteome expression between the atheroscle-
rosis and control groups would be due to the presence of mature atherosclerotic plaques and 
not simply induced by the presence of atherosclerosis risk factors. We attempted to identify 
serological markers that would help us distinguish not only those patients with and without 
carotid atherosclerosis but also those who were more likely to become symptomatic. Using RF 
analysis of the entire protein spectra of fractionated serum from patients with and without 
carotid atherosclerosis revealed a 69.2% sensitivity and a 73.2% specificity in predicting the 
presence of atherosclerosis (  table 1  ;   fig. 1  ). These results suggest that a distinctive pattern is 
present in patients with carotid atherosclerosis. The 4 peptide peaks showing the greatest ef-
fect in the RF analysis that discriminated between these groups had apparent molecular mass-
es of 4.2, 4.4, 16.7 and 28 kDa. However, this approach did not discriminate between the pa-
S pot  No. 
(identifier)
Mean av  erage spot volume8SD p value Protein 
ID
MASCOT 
score
Peptides
asymptomati c symptomatic
6 283874 153842 0.0001 HPT 19 VGYVSGWGR
(17,006) YVMLPVADQDQCIR (C) (M)
OR2T6 13 AVMTSGGWR (M)
FHL1 11 VSHPVSKAR
7 128851 2938238 0.0028 MELT2 13 LSRLLKPGGMMLLR (M)
(16,816) SUCB1 12 ALIADSGLKILACDDLDEA (C)
PCDG9 11 GRLVLLCSLLGMLWEAR (C)
8 103846 240883 0.0015 LRG 35 DLLLPQPDLR
(16,843) TLDLGENQLETLPPDLLR
10 106827 63838 0.0115 A1AT 116 FLENEDR
(16,862) WERPFEVK
DTVFALVNYIFFK
LQHLENELTHDIITHDIITK
VFSNGADLSGVTEEAPLK
DTEEEDFHVDQVTTVK
TLNQPDSQLQLTTGNGLFLSEGLK
11 142848 74836 0.0015 A1AT 134 FLENEDR
(16,868) WERPFEVK
DTVFALVNYIFFK
TDTSHHDQDHPTFNK
LQHLENELTHDIITH
VFSNGADLSGVTEEAPLK
DTEEEDFHVDQVTTVK
LYHSEAFTVNFGDTEEAK
ELDRDTVFALVNYIFFK
LYHSEAFTVNFGDTEEAKK
GTEAAGAMFLEAIPMSIPPEVK (M)
Spot   9 was identified as keratin. (C) = Carbamidomethyl; (M) = oxidation.
Table 3 (continued)125
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  Fig. 4.  Normalized fluorescent intensity values from each albumin-depleted sample of the three most sta-
tistically significant, differentially expressed spots observed by 2D-DIGE. The gray lines represent the 
mean from each group, while the red lines delineate standard deviations. Sample numbers are shown on 
the x-axis of each graph. 126
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tients with symptomatic versus asymptomatic carotid artery disease. This may reflect a limi-
tation of the SELDI-TOF methodology as well as the smaller sample size of this subgroup 
analysis. The 28.1-kDa peak was reduced in patients with atherosclerosis and identified as 
ApoA  1   based on a comparison of the signal characteristics to our SELDI database   [19]  . ApoA  1  
is a hepatic immediate-early response protein and a major component of high-density lipopro-
tein (HDL). It has antioxidant and anti-inflammatory actions and low HDL cholesterol and 
low ApoA  1   levels have been found to be significant risk factors for all types of stroke   [23, 24]  .
    Using 2D-DIGE, we examined a subset of 20 patients with symptomatic or asymptom-
atic carotid atherosclerosis. Four proteins were differentially expressed and significantly dif-
ferent between these two subgroups and were identified as HPT, A  1 AT, VTDB and LRG. Two 
of these proteins, HPT and A  1 AT are part of a panel of acute-phase reactants termed inflam-
matory-sensitive plasma proteins (e.g. fibrinogen, A  1  AT, HPT, ceruloplasmin and orsomu-
coid) that have been shown in large cohort studies to be major risk factors for stroke   [13]  . 
Hypercholesterolemia in association with elevations in inflammatory-sensitive plasma pro-
teins increases the risk of cardiovascular disease, ischemic stroke and myocardial infarction 
whereas in the absence of the proteins, no association was found between hypercholesterol-
emia and ischemic stroke  [13] . These plasma biomarkers modify the risk of stroke in patients 
with hypercholesterolemia, hypertensive patients, and patients with obesity and diabetes  [13, 
18, 25]  . A recent study showed similar findings using an inflammatory score based on white 
blood cell count, HPT and C-reactive protein that added predictive information above that 
of total cholesterol and triglycerides to predict major cardiovascular events (stroke, myocar-
dial infarction or heart failure) in a healthy cohort over 1 decade   [26]  .
    HPT has several functions that may serve as a cofactor in symptomatic atherosclerotic 
disease. It is an acute-phase reactant that binds free hemoglobin, serves as an antioxidant and 
induces anti-inflammatory cytokines   [27]  . HPT also binds to ApoA  1   on HDL, a site that is 
critical for lecithin cholesterolacyl transferase activity and may help bind hemoglobin to 
HDL making it a potentially proatherogenic molecule   [27, 28]  . A strong association of in-
creased risk of micro- and macrovascular cardiovascular disease in patients with the Hp2:    2 
genotype and diabetes has been described   [27]  . Its role in non-diabetic cardiovascular dis-
ease remains to be defined   [29]  .
  VTDB is a major plasma carrier of vitamin D and its metabolites  [30] . In addition, VTDB 
has other important functions, including scavenging actin, fatty acid transport, macrophage 
activation and enhancement of neutrophil and macrophage chemotaxis to C5 des Arg   [30, 
31]  . Stressed endothelial cells release VTDB that has both a chemotactic function and serves 
as a growth factor for vascular smooth muscle cells  [32] . Actin filaments released from dam-
aged cells have the potential to damage the vasculature and enhance thrombosis   [33]  . Re-
cently, VTDB has been found in both the serum and thrombotic plaques of patients with 
acute myocardial infarction   [34]  . VTDB administration in vitro decreased platelet aggrega-
tion and prolonged coagulation   [34]  . Further, patients with acute coronary syndromes have 
persistent elevation of plasma VTDB over 6 months compared to healthy volunteers  [35] . We 
show that VTDB is present in patients with carotid artery atherosclerosis and that patients 
who were symptomatic prior to EA have lower levels of VTDB. Lower levels of VTDB in our 
symptomatic EA patients may have enhanced atherogenesis or contributed to an unstable 
atheromatous plaque.
    LRG was elevated in symptomatic EA patients. It is an acute-phase reactant induced by 
proinflammatory cytokines, and increased expression has been found in several inflamma-
tory conditions, including the sera of patients with graft-versus-host disease, lung and pan-
creatic cancer and in the cerebrospinal fluid of patients with normal pressure hydrocephalus 
  [36]  . LRG is upregulated during neutrophilic differentiation and is localized in azurophilic 
granules  [37] . It binds to cytochrome c, a proinflammatory mediator, and is toxic to lympho-127
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cytes  [36, 38] . The inflammation-modifying effects of LRG in the pathogenesis of atheroscle-
rosis remain to be defined.
    Multiple strategies are necessary to find new biomarkers associated with carotid athero-
sclerosis   [39, 40]  . Our study describes preliminary observations regarding biomarkers associ-
ated with symptomatic and asymptomatic carotid artery disease. Limitations of our study are 
based in part on its size and methodology. The SELDI platform is a semiquantitative tool for 
proteomic discovery and hypothesis generation. It provides spectral patterns that are rich with 
information, but limitations of this approach have been noted  [39, 41] . In our patients, the tim-
ing of blood sampling after the acute event may have influenced our analysis. Some proteins 
may be upregulated during recovery from the acute event rather than representing a specific 
marker of carotid artery disease. Biomarkers measured in serum may not necessarily reflect 
biologic activity at the level of the plaque and may also be influenced by other factors, such as 
degradation in the serum, tissue metabolism and excretion. Lastly, our study did not control 
for the effects of different therapies (i.e. statins, cyclooxygenase inhibitors or antihyperten-
sives) that may have unrecognized effects on the differentially expressed proteins. Our obser-
vations will require validation in other well-defined cohorts at risk for cerebral ischemia.
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